A Phase 2/3 interventional study of nalbuphine HCl ER tablets 60 mg BID and nalbuphine HCl ER tablets 120mg BID in Uremic Pruritus and Pruritus, sponsored by Trevi Therapeutics. Completed at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by Trevi Therapeutics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.
Among the 163 studies in Pruritus with a site in United States, this one is the 17th largest by enrollment of the 153 interventional ones that give a count, is one of 9 that started in 2014, is one of 5 in phase 2/3, and was the 43rd registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Integrative Skin Science and Research · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 69 · Phase 3 48 · Phase 4 13
First in 2000; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 373 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 70 across the 153 interventional studies, 80 across the 9 observational. Of the 126 that completed or were terminated, 80 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 163 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 5 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
12 of the studies in Pruritus with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07450716Massachusetts General HospitalAssessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT07074977Galderma R&DProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 163 studies in Pruritus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and tolerability in the study population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
nalbuphine HCl ER tablets 60 mg BID
Drug: nalbuphine HCl ER tablets 60 mg BID
nalbuphine HCl ER tablets 120 mg BID
Drug: nalbuphine HCl ER tablets 120mg BID
Placebo tablets BID
Drug: Placebo tablets BID
nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
Also known as: nalbuphine ER
nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
Also known as: nalbuphine ER
Placebo tablets BID administered for 8 weeks
Also known as: sugar pill
Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale
The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement.
Time frame: 8 weeks
| Milestone | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill |
|---|---|---|---|
| Started | 128 | 120 | 125 |
| Completed | 74 | 78 | 101 |
| Not completed | 54 | 42 | 24 |
The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement.
| units on a scale | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill |
|---|---|---|---|
| Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale | -3.10 ± 2.35 | -3.49 ± 2.37 | -2.80 ± 2.22 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nalbuphine HCl ER 60mg | 0/126 (0%) | 16/126 (12.7%) | 0/126 (0%) |
| Nalbuphine HCl ER 120mg | 0/120 (0%) | 8/120 (6.7%) | 0/120 (0%) |
| Sugar Pill | 0/123 (0%) | 19/123 (15.4%) | 0/123 (0%) |
| Event | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 4/126 | 1/120 | 0/123 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 4/126 | 0/120 | 0/123 |
| HyperkalemiaMetabolism and nutrition disorders | 2/126 | 1/120 | 3/123 |
| Fluid overloadMetabolism and nutrition disorders | 1/126 | 1/120 | 2/123 |
| SyncopeNervous system disorders | 0/126 | 0/120 | 2/123 |
| AnaemiaBlood and lymphatic system disorders | 2/126 | 0/120 | 2/123 |
| PneumoniaInfections and infestations | 0/126 | 0/120 | 2/123 |
| SepsisInfections and infestations | 0/126 | 0/120 | 2/123 |
| DiarrhoeaGastrointestinal disorders | 0/126 | 1/120 | 0/123 |
| Transient ischemic attackNervous system disorders | 1/126 | 1/120 | 0/123 |
Of the initial 373 participants randomized, 4 were never treated and, therefore, are not included in baseline demographic or frequency tables of treatment emrgent adverse events (TEAEs). Thus, the number of treated particpants was 369.
| Age, Continuous(years) | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill | Total |
|---|---|---|---|---|
| Mean | 55.0 ± 12.1 | 55.2 ± 12.2 | 56.5 ± 13.0 | 55.6 ± 12.4 |
| Sex: Female, Male(Participants) | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill | Total |
|---|---|---|---|---|
| Female | 58 | 51 | 49 | 158 |
| Male | 68 | 69 | 74 | 211 |
| Ethnicity (NIH/OMB)(Participants) | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 20 | 18 | 61 |
| Not Hispanic or Latino | 103 | 100 | 105 | 308 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 | 6 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 66 | 55 | 60 | 181 |
| White | 57 | 62 | 59 | 178 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Nalbuphine HCl ER 60mg | Nalbuphine HCl ER 120mg | Sugar Pill | Total |
|---|---|---|---|---|
| Europe | 23 | 23 | 23 | 69 |
| United States | 103 | 97 | 100 | 300 |
The record gives a start of Jun 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 5 years 2 months after primary completion. A results delay was requested in May 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine